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Western civilization had two great epochs—the sixth century B.C. and the 18th century. The
21st century is likely to be the third great epoch. Although cardiology has advanced more in
the last 50 years than in the previous 2,000, it is likely to advance more in the next two or
three decades than in the previous 2,000 years, including those 50 golden years. The engines
of ingenuity to provide the thrust for the 21th century will come from molecular genetics and
the application of recombinant deoxyribonucleic acid (DNA) techniques. Identification of all
human genes (50,000 to 100,000) in the next two to three years will help link thousands of
etiologies and risk factors with their respective diseases, which represents a new paradigm in
medicine. This is illustrated by the implications to be drawn from familial hypertrophic
cardiomyopathy and the 50 new genes already identified to be responsible for cardiac disease.
The hope for prevention and treatment of human disease is unprecedented. Twenty diseases
account for 80% of the deaths in the Western world and are due to 100 to 200 genes, all of
which will be available in a couple of years. The Phoenician alphabet (inclusive of the Greek
vowels) of 26 letters launched two millenniums of Western civilization, whereas the DNA
alphabet of only four letters will launch and dominate the next millennium. (J Am Coll
Cardiol 2000;36:661–7) © 2000 by the American College of Cardiology
Western civilization is noted for two great epochs—namely,
the 6th century B.C. and the 18th century A.D. 4859 (1).
The high level of conceptual thinking of the Greeks in the
6th century B.C. led to the birth of Western philosophy and
democracy from which evolved the foundations of Western
civilization. The widespread use of the phonetic alphabet is
arguably a major factor that contributed to the success of the
6th century B.C. The alphabet (defined as one with ,30
symbols), claimed to be developed by the Semites (Phoene-
cian), had no vowels. There were written languages be-
fore—namely, hieroglyphics (Egyptians), cuneiform (Sum-
erians) and Chinese characters—but these were all pictorial
and emphasized concrete thinking. The alphabet, with its
symbols, was simple and stimulated abstract thinking. The
addition of the vowels, probably between the 9th and the
6th century B.C. by the Greeks, is thought to have signif-
icantly facilitated the translation from the spoken to the
written world. It is well recognized that translating the
spoken word into the written word of Indo-European
languages is very difficult without vowels (2). The 18th
century brought the Industrial Revolution, a uniquely West-
ern contribution, which started us on the road to modern
technology and has continued at an accelerating rate. From
the 15th to the 18th centuries, European explorers took
Western civilization to all corners of the Earth, as remarked
by Captain Cook, on reaching Australia in 1770 (3): “Not
only have I traveled farther than any man has traveled, but
I have traveled as far as man can travel.” There is little doubt
that the 6th century B.C. molded our society for the next
two millenniums, and the Industrial Revolution of the 18th
century continues to improve the living conditions of all
mankind. A comparable timeline for the history of medicine
starts in Greece on the island of Cos with Hypocrates, the
founder of modern medicine. The Greeks pursued medicine
with great intensity, but throughout the Dark Ages and the
Christian and Islamic religious eras, when medicine expe-
rienced some significant advances, for the most part, science
was stifled. Evolution of reason and scientific thought after
the Renaissance restored a progressive approach to science
and medicine. Nevertheless, just over 60 years ago (1931),
Paul Dudley White boldly stated there was no effective
treatment for valvular disease, coronary artery disease, hy-
pertension or syphillis (4). In the 1940s, sulfonamides and
penicillin were introduced, followed by an explosion that
ushered in the modern era of cardiology. Cardiology has
without doubt advanced more in the last 50 years than in the
previous 2,000 years. Today, the heart is just another work
place we invade with a variety of tools such as the coronary
catheter, the angioplasty catheter, bypass grafts, pacemakers
and a host of others. Their application, along with preven-
tive medicine, in the past 30 years has resulted in an
astounding 60% reduction in the death rate from heart
disease (5). It is reasonable to assume the 21st century will
be the third great epoch for our civilization, and it is likely
to be evident in the next 20 to 30 years, as I believe
cardiology will advance more in the next two to three
decades than it has in the previous 2,000 years, including
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that great golden age of the last 50 years. The engines of
ingenuity to provide the thrust for the 21st century will
come from molecular genetics and the application of recom-
binant deoxyribonucleic acid (DNA) techniques.
In the 20th century, man has mapped the earth, its oceans
and explored its inner composition. We have experienced
the excitement of the gold rushes and the oil gushes and
characterized Earth’s precious gems and metals. We have
seen the development of the physicist’s table of elements
that in turn led to many exciting innovations. The 21st
century will be ushered in by the new science of molecular
biology, based on the fundamental units of mankind that are
responsible for passing on all of the inheritable characteris-
tics—DNA. For the first time, the biologist and the
physician will march together with their complete table of
elements, and it will not be a list of inorganic components
but rather the 50,000 to 100,000 genes responsible for one
human. Knowing the genes and their functions will have
universal appeal and invoke interest from all phases of
medicine, science, philosophy, ethics, the arts and govern-
ment—it will be as Francis Collins has stated, a “code for
the book of life” (6). The DNA code uses four letters: A
(adenine), G (guanine), C (cytosine) and T (thymine).
These letters are strung together into distinct units referred
to as genes, which give rise to a unique protein destined for
a distinct morphologic location and function within the
human body. These proteins are responsible for every action
that a human being performs. Thus, most of what we do and
how we do it is strongly influenced by the sequence of these four
letters. The Phoenecian alphabet (inclusive of the Greek
vowels) of 26 letters launched more than two milleniums of
Western civilization, whereas the DNA alphabet of only
four letters will launch and dominate this millennium.
Although progress will continue on the inner structure of
the Earth and great strides are likely to be made in exploring
our galaxy, the hallmark of the 21st century will be the
exploration of the inner workings of a human being. To use
a phrase from the old millennium: “Your genes will be up in
your face.”
The human genome, contained in 23 chromosomes,
consists of three billion bases with an estimated 50,000 to
100,000 genes. The genes (made of exons) make up about
3% of the DNA, and the in-between sequences (introns)
have an unknown role so far. The Human Genome Project,
initiated in 1990 (7), was to sequence all of the DNA,
including the genes, by the year 2005. Commercial efforts
announced that all of the human genes would be sequenced
by the year 2001 (8,9). The Human Genome Project has
also been progressing more rapidly than expected. It was
predicted that half of the human genome would be com-
pleted by the year 2001 and the remainder by 2003 (10).
More recently, with the boost in funding for the three major
U.S. players (Baylor College of Medicine, Washington
University and The Whitehead Foundation), it is predicted
that a rough draft of 90% of the human genome will be
available by March 2000 (11).
The new paradigm for cardiology and medicine—
etiologic and individualized treatment. Despite our
knowledge of diagnosis and treatment, we seldom know the
etiology or the specific molecular defect responsible for
disease, and thus our therapies are not as specifically
targeted as one would desire. In the next couple of years,
regardless of when the Human Genome Project is com-
pleted, there will be at least 30,000 genes available, and thus
we will have thousands of etiologies and specific molecular
defects to be linked with their respective disease. This will
represent an entirely new paradigm in the field of medicine.
Similarly, in the field of preventive medicine, there will be
thousands of genetic risk factors that will need to be
matched with diseases for which they are predisposed. We,
as physicians, are taught to treat the crisis, and until the
1990s, physicians who saw and treated a high percentage of
normal individuals were considered perhaps to be nondis-
criminatory in applying the art of medicine. Prevention will
be the key to future successes, and the unraveling of human
genes will catapult prevention as a major initiative for the
21st century. In the management of coronary artery disease,
individuals will be identified in their teens so that treatment
and prevention appropriate for their medical risk profile and
life style can be properly individualized. Treating coronary
artery disease after the crisis of myocardial infarction, when
a part of the myocardium has already been lost to scar, will
be seen in the 21st century as negligent and a missed
opportunity. It is evident from present day knowledge that
primary prevention of atherosclerosis is far more effective
than treating acute myocardial infarction. The massive array
of specific etiologies and risk factors will be truly staggering,
and it is for this reason that all of us as physicians must at
least become acquainted with the new terminology. The
area of pharmacogenomics (12), although now only in its
infancy, will rapidly evolve in the next 10 years. Individu-
alization of therapy, the antithesis of health maintenance
organizations and managed care, will be the norm.
Angiotensin-converting enzyme (ACE) inhibitors may be
more effective than angiotensin one (AT-1) receptor block-
ade for the hypertensive patient who has expressed a
vulnerable polymorphism in the ACE, whereas the latter
might be more appropriate for those with an expressed
vulnerable polymorphism in the AT-1 receptor. Because the
genes present in the DNA of a white blood cell are identical to
the genes in the cell of any other organ (brain, heart, etc.), these
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ARVD 5 arrhythmogenic right ventricular dysplasia
AT-1 5 angiotensin one
DNA 5 deoxyribonucleic acid
EST 5 expressed sequence
FDCM 5 familial dilated cardiomyopathy
FHCM 5 familial hypertrophic cardiomyopathy
HCM 5 hypertrophic cardiomyopathy
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genetic etiologies and risk factors responsible for diseases can be
detected from analysis of a single blood sample (13). The
development of DNA as a computerized chip will make it
possible to screen for thousands of mutations within a few
hours. It was realized very early in the genetic revolution
that there would have to be a new science (bioinformatics)
to store and retrieve such massive information. A comput-
erized network of gene banks was established in London,
Washington and Tokyo and made available to PC users
throughout the world. The GenBank has stored over two
billion bases of DNA from 39,000 species (6) and 1,000
genes with 20,000 mutations known to cause human disease
(14). The establishment of computer terminals at nursing
stations throughout hospitals will provide access to the
computerized gene data bases so that genetic information is
immediately accessible to the clinician and paramedical
personnel.
Progress in cardiovascular genetics. Until recently, it was
possible to identify only genes responsible for disease if one
knew the specific protein, whereas today, by using a tech-
nique of genetic linkage analysis to map the chromosomal
location of the gene and positional cloning, one can identify
the gene without knowing the molecular nature of the
defect or the responsible protein (15). The ultimate goal of
the Human Genome Project was to sequence the human
genome; however, other important objectives were com-
pleted along the way. A genetic map was developed with
over 6,000 chromosomal markers placed throughout the
human genome at intervals of less than one million bases.
This revolutionized the mapping of the chromosomal loca-
tion (locus) of disease-related genes. The success of genetic
linkage analysis is directly proportional to the quantity and
quality of the markers available to map the chromosomal
location of a gene. The development of the genetic map
made it possible in a three-generation family to map a locus
in months to weeks as opposed to several years. The other
objective was the tagging of unique expressed sequences
(EST) with the hope that each tag would represent a
distinct gene. A map of over 40,000 ESTs has been
developed, which, in conjunction with the list of genes
already mapped, has rapidly accelerated identification of
genes responsible for disease (16). The first primary cardio-
myopathy to succumb to genetic linkage analysis was famil-
ial hypertrophic cardiomyopathy (FHCM) (17), and beta-
myosin heavy chain (beta-MHC) was shown to be the
responsible gene (18). In 10 years, there has been an
avalanche of genes associated with a variety of diseases of
the heart. Over 50 genes known to cause heart disease have
been mapped to their chromosomal location (19). Eight
genes responsible for HCM have been identified with over
100 mutations. Although nine loci have been identified
(mapped) as responsible for familial dilated cardiomyopathy
(FDCM), only two genes have been identified—actin (20)
and desmin (21). Four loci (22) have been identified as
responsible for cardiomyopathies of the right ventricle—
namely, arrhythmogenic right ventricular dysplasia
(ARVD). Several genes have been identified in the mito-
chondrial DNA to be responsible for cardiomyopathies
(23). Genes have also been identified as responsible for
ventricular arrhythmias, supraventricular arrhythmias, con-
duction disorders, anatomic defects (septal, aortic) and
neuromuscular disorders affecting the heart (see review in
[19]). In addition, several genes that cause lipid disorders,
hypertension and various vascularopathies have been iden-
tified. Many other genes present in the invertebrate and
vertebrate heart have been identified and shown to play a
major role in the development of the heart, which will
accelerate the finding of their analogues in the human heart
(24). The genetics of cardiac development is progressing in
simpler organisms such as the zebra fish and the chicken
embryo and from genes identified as responsible for inher-
ited cardiac developmental defects. These pathways of
investigation will merge and accelerate the identification of
genes responsible for early cardiac development, while at the
same time they will provide fundamental insight into
understanding the cardiac growth response.
Familial hypertrophic cardiomyopathy as an illustrative
example of genetics for the 21st century. Familial HCM,
an autosomal-dominant disease, is the most common cause
of sudden death in the young, particularly in the athlete.
Familial HCM is more common than realized, occurring
with an incidence of one in 1,000 in the population. It is
associated with cardiac myocyte and filament disarray,
hypertrophy and increased fibrous tissue (25). This is a
disease that represents a paradigm of the hypertrophic
response of the heart to injury. The heart adapts to injury,
whether physiologic or pathologic (e.g., pressure or volume
overload), through one of two growth responses—namely,
hypertrophy or dilation, or both (26). Familial HCM
represents the hypertrophic response, whereas FDCM rep-
resents a paradigm of the dilated form. It remains to be
determined whether cardiac dilation is a growth response. It
has been postulated that it is a normal growth response in
which the sarcomeres are added in sequence as opposed to
in parallel (in hypertrophy); however, it could represent an
impaired growth response (27). In athletes, the response
consists of hypertrophy and dilation and returns to normal
with cessation of exercise, suggesting that both responses are
normal. However, it has not been shown morphologically
that sarcomeres are formed in parallel in athletes. The
hypertrophy of FHCM, although eccentric in 80%, often
becomes concentric but is almost exclusively in the left
ventricle, with ,5% involving the right ventricle. The first
gene identified to be responsible for FHCM was beta-
MHC at 14q1 (17). Since that time, there have been six
other genes identified—troponin T, tropomyosin C, tropo-
nin I, myosin-binding protein C and the two myosin light
chains (28). Although there are other genes to be identified,
experience with genotyping new families with FHCM
suggests that most of them are due to one of the known
genes. On the basis of our data base of over 3,000 individ-
uals with FHCM, the beta-MHC gene accounts for .50%
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of the patients, and myosin-binding protein C together with
troponin T accounts for another 30%; the results published
by Seidman et al. (29) are similar. Thus, it is likely the seven
known genes are responsible for 80% to 90% of FHCM. It
is important to emphasize that essentially all of the cases of
HCM (excluding those with known acquired causes) have a
genetic basis, but some are sporadic rather than familial. Of
course, once a sporadic de novo mutation occurs, it is highly
likely to become familial in the next generation, although
mutations with very low penetrance may not be expressed in
all generations. There are over 100 mutations now identified
in the seven genes responsible for FHCM, and most are due
to a single base substitution that results in the substitution
of one of the amino acids; however, a few are due to small
deletions or insertions.
From genotype–phenotype correlations, it is rare to
observe any clinical, electrocardiographic or echocardio-
graphic features of FHCM before puberty (30–33). Rare
cases have been observed before puberty, but they probably
are homozygous from both parents having the disease. The
lack of disease before puberty provides an important time
window for prevention when such therapy becomes avail-
able. After puberty, the age of onset is highly variable, and,
as stated previously, in HCM due to the myosin-binding
protein C gene, onset may not occur until the fifth or sixth
decade of life. Second, the presence or absence of clinical
features, even within the same family, is highly variable.
Third, the incidence of sudden death is highly variable and
does not correlate with the presence or severity of any of the
clinical features. In patients with FHCM due to troponin T
mutations, there is very little cardiac hypertrophy but a high
incidence of sudden death (34). In patients with FHCM
due to mutations in the beta-MHC gene, there is consis-
tently hypertrophy, but the incidence and frequency of
sudden death are highly variable. Last, several studies by
several investigators have shown a strong correlation be-
tween the incidence of sudden death and the type of
mutation (32,35,36). This is illustrated in Figure 1, which
shows that patients with the Arg4033Gln mutation have
an average life span of 28 years compared with an average
life span into the 60s with the Glu9303Lys mutation (37).
In a collaborative study with Seidman’s group, we observed
an interesting correlation between age of onset of the disease
and mutations in the myosin-binding protein C (38). The
analysis consists of 16 unrelated families with a total of 574
members; we found 12 novel mutations, with 212 affected
individuals. The onset of the disease was very age depen-
dent, with many individuals exhibiting no manifestations of
the disease until they were in their fourth or fifth decade of
life. This finding is relevant to the so-called HCM of the
elderly, which is assumed to be an acquired disease but may
be genetic with expression in the seventh or eighth decade.
In summary, only the mutations correlate with the incidence
of sudden death. On the basis of the observation of a large
number of families, we have observed that Arg4033Gln,
Arg4533Crs, Arg7193Trp predict an average life span of
28 years, whereas the mutation Glu9303Lys, Arg3249-
Gln has a life span of 43 years, and Leu9083Val,
Val6063Met, Cly2563Glu of 62 years. It should be
emphasized that while certain mutations appear to be
predictive, other factors are very important—namely, inter-
actions with other genes and environmental stimuli. These
factors hopefully will be elucidated and shown to explain the
variation that occurs in the phenotype of this disease, even
within the same family with the same mutation. The
importance of environment on expression of the mutant
gene is amply illustrated by FHCM, in which the disease is
seldom seen in the right ventricle despite the mutant gene’s
presence in equal abundance in the right and left ventricles.
This is similarly illustrated in ARVD, in which the disease
is present primarily in the right ventricle. Gene-to-gene
interaction is emphasized by the observation that FHCM
mutations occurring in individuals with the DD allele of the
ACE genes have more extensive hypertrophy and a higher
incidence of sudden death. Because the genes present in the
DNA of a white cell are identical to those in the heart or brain,
a blood sample provides immediate access to all genes (39).
Thus, a new era will dawn with the ability to genotype for
all diseases; a specific diagnosis can be made using a single
blood sample, enabling a rational basis for their prevention
and treatment. It is awesome and scary to realize that a
single blood sample will provide the specific etiology of
thousands of diseases. In the near future, as we learn more
about factors that affect gene penetrance and expression,
genotyping will provide not only a more specific diagnosis,
but also a basis to risk, stratify, and select more appropriate
individual therapy.
Genetic surprises. As more and more genes become avail-
able, it is highly likely that many defects not previously
considered to have a familial origin or disposition will be
shown to have a genetic component. One example of this is
Figure 1. Kaplan-Meier survival curve showing the correlation between the
incidence of sudden death and the type of mutation (35,36). This shows
that patients with the Arg4033Gln mutation have an average life span of
28 years as compared with an average life span into the 60s with the
Glu9303Lys mutation.
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atrial fibrillation (AF), which hitherto was regarded as an
acquired disease. In 1996, we identified a family with early
onset of AF and mapped the genetic defect to chromosome
10q22 (40). The disease is inherited as autosomal dominant
and is probably far more prevalent than expected, since over
100 families have been identified and loci heterogeneity has
been demonstrated (41). In Italy, ARVD is a disease that is
the most common cause of sudden death in the young. It
initiates in the right ventricle and only much later in life
does there appear to be left ventricular involvement. Does
this mean there is a chamber-specific gene? Or does it mean
that a stimulus specific for the right ventricle interacts to
develop this phenotype? It is more likely the latter because
other cardiomyopathies that develop in the left ventricle
seldom involve the right ventricle, even though the defective
gene is equally abundant in the right ventricle. Three loci
have been mapped responsible for ARVD (42–44) in
families from the Veneto region in Italy and in another
family in Greece (44). In 1998 (22), a gene was mapped to
chromosome 3p23, responsible for ARVD in a family from
North America, and a second locus to 10p12 (45). It now
appears that ARVD may account for up to 15% of sudden
deaths in the young in North America (46).
Genetic animal models and inherited human disease—
the hope for functional genomics and improved therapy.
The excitement and challenge for the next few decades will
be in determining the function of the genes. At present, we
have the ability to identify about 2,000 proteins, so we are
missing only 48,000 to 98,000. In a symposium held in Cold
Spring Harbor, we estimated that if 15 mouse clinics were
established in the U.S. and one gene was knocked out each
week, it would take 77 years to identify the function of the
unknown genes (47). The physician investigator is facing a
very bright future. Relating the phenotype of inherited
diseases and physiologic functions observed at bedside to
their responsible gene(s) will markedly accelerate functional
genomics. There has never been a more exciting and
opportune time for the physician investigator; molecular
genetics is the preeminent field for translational research.
Gene transfer into cultured cardiac myocytes (48,49) or
into germ lines to induce transgenic animals (50–53), or
elimination of genes through homologous recombination
(knockouts), remain the prime methods to elucidate the
molecular basis for disease. Such experiments have been
performed with the human mutant beta-MHC and tropo-
nin T genes, and the resulting phenotype is similar to the
FHCM phenotype observed in humans. It is of interest that
the mutant beta-MHC gene or troponin T gene induces in
transgenic mice a phenotype of myocyte disarray, increased
fibrous tissue, impaired systolic and diastolic function and
sudden death, but minimal hypertrophy. In contrast, trans-
genic rabbits generated using a human mutant beta-MHC
gene exhibit all of those features and also significant
hypertrophy (54). On the basis of a variety of animal studies
and certain clinical observations, it would appear that the
myocyte hypertrophy and fibroblast proliferation is second-
ary to the impaired myocyte contractility induced by the
mutant protein. The growth factors responsible for the
myocyte hypertrophy appear to be different from those
responsible for fibroblast proliferation, as judged from the
results in these two models. In the rabbit, both hypertrophy
and fibrous tissue are increased, whereas in the mouse, it is
primarily fibrous tissue, and thus it might be possible,
utilizing the two models, to distinguish through subtraction
hybridization between the genes responsible for these two
growth responses. Isolation of the responsible growth factor
for each or both will undoubtedly lead to the development
of specific therapies that can be used to induce growth (e.g.,
after myocardial infarction) or inhibit it (e.g., FHCM).
Given the window of opportunity that exists for most
autosomal-dominant diseases—namely, years to decades
before the development of the disease (e.g., FHCM)—a
variety of agents can be assessed to determine their benefi-
cial effect in animal models of genetic disease. Several
animal models of FHCM have been generated, and studies
are ongoing to assess drugs such as ACE inhibitors to delay
or attenuate the hypertrophic response. It is estimated that
the human heart renews itself about every three weeks, and
in the hypertrophic heart, that also includes the fibroblast
and its matrix. Thus, if the mutant gene could be inhibited
and the myocardium renews itself by utilizing the normal
gene, one would expect a new and normal heart in four to
five months. The technology to test this hypothesis in
animal models in which the expressed mutant gene can be
turned off after the development of the phenotype appears
to be on the horizon. If the results of such studies show that
the FHCM phenotype, with its morphologic and functional
abnormalities, is reversible, it will provide a great impetus
for the development of therapies designed to inhibit expres-
sion of the mutant gene.
The GenBank (referred to earlier) will also play a major
role in functional genomics. In parallel to the sequencing of
the human genome, several small genomes of single cells are
also being sequenced. The first genome to be completely
sequenced, and all of its genes identified, was Haemophilis
influenza in 1995 with 1.4 million bases. Since 1995, over 40
single-cell organisms have been sequenced, including the large
organism Saccharomyces cerevisiae with a genome of 12
million bases. This paved the way for the development of
novel antibiotics targeted to specific genes. However, the
most significant development occurred at the end of 1998
with the sequence of C. elegans (55). This is the first
multicellular organism for which the genome has been
sequenced; it has 97 million base pairs and 19,000 genes,
one-fifth the number of human genes. Furthermore, a
significant percentage of the genes identified are identical to
those of human genes. In C. elegans, all 959 cells that make
up this tiny worm have been recognized, and because of its
transparent skin, it is possible to observe the development of
this organism and determine the function of each gene and
its morphologic phenotype (56). Although humans may
have up to 100,000 genes, it is highly likely that many of
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these genes belong to families with common consensus motifs
that share a specific similar function. An example of this would
be kinases, which transfer high energy phosphate from one
molecule to the other, a common process throughout the body.
There are over 3,000 genes that encode kinases, but all of those
have in common a sequence motif and the function of
transferring high energy phosphate. The development of the
gene bank of different genes from different species now makes
it possible to travel back about one billion years in time. This
will help tremendously in determining the function of genes. A
DNA sequence of unknown function can be aligned to a DNA
sequence in the gene bank from other species. If the function
of the sequence is known in another species, a similar function
will most likely prevail in humans. It will also play a large role
in understanding evolution, this time at the molecular level—
namely, the gene that has been altered—rather than studying
the evolutionary change expressed through the phenotype.
A look into the future. The Human Genome Project has
been compared to that of the Apollo or the Manhattan
Project. The impact of the Human Genome Project, in my
opinion, is likely to be far greater than that of either the
Apollo or the Manhattan Project. The technology to geno-
type thousands of mutantions through use of technology
such as the DNA chip or mass spectrometry is progressing
rapidly and promises to have an assay turnaround time of
hours. This will make available all of the human genes and
their variants. Development of this technology and the
completion of the human genome will provide clinical
access to thousands of genetic risk factors and specific
etiologies. Genotyping for gene variation will provide a new
era for selecting appropriate drugs (pharmacogenetics). For
example, a hypertensive individual with the DD form of the
ACE gene would more likely respond to an ACE inhibitor,
whereas someone with a gene variant causing increased
catecholamines would more likely respond to a beta-
blocker. The elucidation of the pathogenesis of disease in
genetic animal models provides specific molecular targets
for drug development. The target is not just the defective
molecule inducing the disease, but also the additional
targets upstream and downstream from this molecule,
which comprise the pathway of signaling proteins and other
necessary substrates. An example may be the work of Brown
et al. (57) on elucidating the cholesterol receptor in familial
hypercholesterolemia. This disease is responsible for per-
haps ,1% of heart disease, but today drugs inhibiting the
cholesterol synthetic pathway are also first-line treatment
for acquired forms of the disease. Similarly, unraveling the
molecular defect for familial AF should elucidate a pathway
essential to normal conduction and is involved with acquired
forms of AF. Although the human body has hundreds of
trillions of cells, there are only about 200 different cells that
have a unique function. The recent research on pleuripotent
stem cells has laid the groundwork for stimulating these
cells to develop into the cell or organ of choice. It is well
established that myoD stimulates a fibroblast to convert into
a skeletal muscle myocyte. The National Heart, Lung, and
Blood Institute of the National Institutes of Health (Be-
thesda, Maryland) has proposed a new goal under the term
“restorative biology” to grow human organs (heart, lung and
brain) over the next 10 years. Gene therapy for solid organs
has not yet been effective, but the ease of ex vivo gene uptake
into organs such as veins for bypass grafts or the explanted
heart for transplantation into the donor makes this a likely
success in the near future. We now know that 20 diseases
account for 80% of the deaths in the Western world, and it
is reasonable to assume that only about 100 to 200 genes are
involved in these diseases. All of those genes will be
available in a couple of years, and the implications of genetic
screening for prevention or of new therapies resulting from
targeted development are enlightening and staggering. The
implications of the human genome for the prevention and
treatment of disease are greater than we can imagine. It was
once postulated that our genes would all be on a CD-ROM
and available during an interview, such as for employment
by the year 2030; this is now possible by 2008. There could
be some casualties, as occur with any revolution, and thus
bioethical considerations must proceed along with the
scientific discoveries (58). Despite the concerns, the proper
application of these techniques should affect a marked
reduction in human suffering from disease, and it has been
predicted that human life span will be prolonged by at least
50% in the next millennium.
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